Investor Library

StemRIMIR Library

All Timely Disclosure Information Financial Results Presentation Materials IR News

March 13, 2026	Timely Disclosure Information	Presentation Material Financial Results for the Six Months Ended January 31, 2026
March 11, 2026	Timely Disclosure Information	Non-consolidated Financial Results for the Six Months Ended January 31, 2026 [Japanese GAAP]
March 2, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (Development Code: SR-GT1) Aimed at Curative Treatment of DEB
February 17, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration (Canada) for the Use of Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
December 25, 2025	Timely Disclosure Information	StemRIM Announces Completion of Patient Enrollment in the Global Phase 2b Clinical Trial of the Redasemtide for Acute Ischemic Stroke
December 17, 2025	Timely Disclosure Information	StemRIM Announces Patent Registration (JP) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Fatty L
December 10, 2025	Timely Disclosure Information	Non-consolidated Financial Results for the Three Months Ended October 31, 2025 [Japanese GAAP]
December 10, 2025	Timely Disclosure Information	StemRIM Announces the Formation of a Compensation Committee on a Voluntary Basis
December 10, 2025	Timely Disclosure Information	StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation
November 12, 2025	Timely Disclosure Information	StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock
October 31, 2025	Timely Disclosure Information	Presentation Material for Business Plan and Growth Potential
October 16, 2025	Timely Disclosure Information	StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (Development Code:SR-GT1) Aimed at Curative Treatment of Dystrophic Epidermolysis Bullos
October 1, 2025	Timely Disclosure Information	StemRIM Announces Patent Registration (US) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Psoriasis
September 26, 2025	Timely Disclosure Information	StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employees and External Collaborator
September 18, 2025	Timely Disclosure Information	StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators